686344-29-6 Usage
General Description
Otenabant is a potent and selective antagonist of the cannabinoid receptor CB1, which is found mainly in the central nervous system. It was developed as a potential treatment for obesity and related metabolic disorders by blocking the activity of CB1 receptors in the brain, which are known to regulate appetite and energy balance. Otenabant was shown to decrease food intake and body weight in animal models and was initially tested in clinical trials for its potential as a weight-loss medication. However, its development was discontinued due to safety concerns, including adverse effects on the liver and cardiovascular system. Despite its promising potential as an anti-obesity drug, Otenabant's use was ultimately not pursued due to these safety issues.
Check Digit Verification of cas no
The CAS Registry Mumber 686344-29-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,6,3,4 and 4 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 686344-29:
(8*6)+(7*8)+(6*6)+(5*3)+(4*4)+(3*4)+(2*2)+(1*9)=196
196 % 10 = 6
So 686344-29-6 is a valid CAS Registry Number.
686344-29-6Relevant articles and documents
Development of a Practical and Efficient Synthesis of CP-945, 598-01, a CBi Antagonist for the Treatment of Obesity
Ragan, John A.,Bourassa, Dennis E.,Blunt, Jon,Breen, Darragh,Busch, Frank R.,Cordi, Eric M.,Damon, David B.,Do, Nga,Engtrakul, Alanya,Lynch, Denis,McDermott, Ruth E.,Mongillo, Joseph A.,O'Sullivan, Maria M.,Vanderplas, Peter R. RoseBrian C.
experimental part, p. 186 - 197 (2010/04/22)
Development of an efficient bond-forming sequence and optimization of reaction conditions are described for the synthesis of CP-945, 598-01 (1-HC1), a CB, antagonist in clinical studies for the treatment of obesity. Reordering of the bond-forming sequence
PROCESS FOR PREPARING PURINE COMPOUNDS
-
Page/Page column 18-20, (2010/11/08)
A process for preparing compounds of Formula (I) are described herein as well as key intermediates.
